Novo Nordisk A/SNVONYSE
Loading
Year-over-year free cash flow growth rate
Latest
-133.28%
↓ 244% vs avg
Percentile
P0
Near historical low
Streak
3 qtr
Consecutive declineDecelerating
Average
92.68%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -133.28% |
| Q3 2025 | 32.51% |
| Q2 2025 | 144.98% |
| Q1 2025 | 335.02% |
| Q4 2024 | -113.42% |
| Q3 2024 | -14.85% |
| Q2 2024 | 602.45% |
| Q1 2024 | 177.05% |
| Q4 2023 | -122.69% |
| Q3 2023 | 40.85% |
| Q2 2023 | -13.88% |
| Q1 2023 | 1068.83% |
| Q4 2022 | -89.31% |
| Q3 2022 | -6.42% |
| Q2 2022 | -1.93% |
| Q1 2022 | 530.44% |
| Q4 2021 | -125.56% |
| Q3 2021 | -15.20% |
| Q2 2021 | 139.56% |
| Q1 2021 | 824.81% |
| Q4 2020 | -111.79% |
| Q3 2020 | -50.12% |
| Q2 2020 | 176.20% |
| Q1 2020 | 154.42% |
| Q4 2019 | -77.12% |
| Q3 2019 | 16.16% |
| Q2 2019 | 78.90% |
| Q1 2019 | 99.74% |
| Q4 2018 | -60.59% |
| Q3 2018 | -34.09% |
| Q2 2018 | 92.66% |
| Q1 2018 | 144.81% |
| Q4 2017 | -74.35% |
| Q3 2017 | 29.74% |
| Q2 2017 | -18.98% |
| Q1 2017 | 23.82% |
| Q4 2016 | -33.34% |
| Q3 2016 | -1.23% |
| Q2 2016 | 101.15% |
| Q1 2016 | -8.76% |